/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes treatments in oncology, inflammation, and autoimmune diseases. Valued at a market cap of $16.5 billion, the company’s portfolio includes drugs such as Jakafi, Monjuvi, Pemazyre, and Opzelura.
Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and Incyte fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the biotechnology industry. The company’s strong R&D focus and global partnerships enhance its ability to bring breakthrough therapies to patients. Its strength lies in its deep expertise in targeted therapies and immunology, supported by a proven track record of successful drug development in oncology and dermatology.
